Compound comparison

cognition

3 RCT / 6 animal / 2 in vitro

nasal

No

Not approved

none

Nootropic: 250-1,200 mcg/day intranasally, split AM/midday. N-Acetyl Semax: 30-40% lower dose, once daily. Stroke (Russian clinical): 9,000-18,000 mcg/day — clinical setting only.

Semax has a plasma half-life of approximately 20-30 minutes — longer than Selank's 2-5 minutes due to the Pro-Gly-Pro extension's greater resistance to peptidase degradation

Mechanism diagram showing the compound's primary signaling pathway and downstream effects.

cognition, sleep, immune

3 RCT / 1 animal / 0 in vitro

nasal

S0

Not approved

none

Intranasal: 250-500 mcg per session (2-5 drops or sprays), 1-2x daily. SubQ: 150-250 mcg daily. Cycles of 10-14 days with breaks standard in Russian protocol; community often runs longer.

~2-5 minutes in plasma. Effects last hours per dose via downstream signaling. Rapid peptidase degradation makes oral bioavailability negligible.

Mechanism diagram showing the compound's primary signaling pathway and downstream effects.

cognition

—

oral

No

Not approved

none

—

—

Mechanism diagram showing the compound's primary signaling pathway and downstream effects.

cognition

0 RCT / 2 animal / 0 in vitro

injectable-sc, nasal

No

Not approved

none

—

—

Mechanism diagram showing the compound's primary signaling pathway and downstream effects.